Диссертация (1141092), страница 18
Текст из файла (страница 18)
964–975.50.Harenberg J., Du S., Wehling M., Zolfaghari S., Weiss C., Kramer R., Walenga J.Measurement of dabigatran, rivaroxaban and apixaban in samples of plasma, serumand urine, under real life conditions. An international study. Clin Chem Lab Med.2016; 54:275-83.51.Harenberg J., Kramer S., Du S., Zolfaghari S., Schulze A., Kramer R., Weiss C.,Wehling M., Lip G.Y.. Measurement of rivaroxaban and apixaban in serumsamples of patients. // Eur J Clin Invest. 2014; 44:743-52.52.Harenberg Job, Laboratory determination of old and new targeted anticoagulantagents for prevention of bleeding and thrombotic events in cancer patients.Thrombosis Research 140S1 (2016) S165-S167.53.Hart R.G. et al. // J Am Coll Cardiol 2000; 35:183–7.54.Heeringa J., van der Kuip D.A., Hofman A., et al.
Prevalence, incidence andlifetime risk of atrial fibrillation: the Rotterdam study. // Eur Heart J 2006; 27: 949–953.11555.Heidbuchel H., Verhamme P., Alings M., Antz M., Hacke W., Oldgren J., SinnaeveP., Camm A.J., Kirchhof P. European Heart Rhythm Association.
European HeartRhythm Association Practical Guide on the use of new oral anticoagulants inpatients with non-valvular atrial fibrillation. Europace. 2013; 15:625–651.56.Helen Mani, Carola Wagner, Edelgard Lindhoff-Last. Influence of NewAnticoagulants on Coagulation Tests. MD 2011 Siemens Healthcare DiagnosticsInc.57.Hernandez I., Zhang Y. Comparing Stroke and Bleeding with Rivaroxaban andDabigatran in Atrial Fibrillation: Analysis of the US Medicare Part D Data. // AmJ Cardiovasc Drugs. 2016 Sep 14.58.Hijazi Z., Oldgren J., Lindbäck J., et al.
The Novel Biomarker-Based ABC (Age,Biomarkers, Clinical History)-Bleeding Risk Score for Patients With AtrialFibrillation: A Derivation and Validation Study. // Lancet 2016; Apr 4.59.Horjen A.W., Ulimoen S.R., Enger S. Impact of atrial fibrillation on levels of highsensitivity troponin I in a 75-year-old population.
// Scand J Clin Lab Invest. 2015Jul;75(4):308-313.60.Hughes M., Lip G.Y.H.,on be half of the Guideline Development Group for theNICE national clinical guideline for management of atrial fibrillation in primaryand secondary care Stroke and thromboembolism In atrial fibrillation: Asystematicreviewof stroke risk factors, risk stratification schema and cost effectiveness data.// J Thromb Haemost 2008; 99:295–304.61.John W., Eikelboom, Jeffrey I., Weitz. Bleeding risk with dabigatran in the frailelderly. // N Engl J Med 2012; 366 (March (9)):864.62.Jonathan Michael Wong.
COMPARING MAJOR BLEEDING RISK INOUTPATIENTSWITHATRIALFIBRILLATIONBYORALANTICOAGULANT TYPE: INSIGHTS FROM THE NCDR® PINNACLEREGISTRY.// JACC April 5, 201663.Kaatz S., Crowther M. Reversal of target-specific oral anticoagulants. // J ThrombThrombolysis.2013;36:195–202.11664.Karen A., Russell D., Lawrence L., Jennifer S. Therapeutic use of warfarin andothervitaminKantagonists.UpToDate19.3.2013.URL:http://www.uptodate.com/home.65.Keeling D. Duration of anticoagulation: decision making based on absolute risk.Blood Rev 2006; 20:173-178.66.Kim J., Yadava M., An I.C., Sayeed A., Laird-Fick H.S., Gourineni V., Abela G.S.Coagulopathy and Extremely Elevated PT/INR after Dabigatran Etexilate Use in aPatient with End-Stage Renal Disease.
Case Rep Med. 2013; 2013:131395.67.Kirchhof P., Benussi S., Kotecha D., Ahlsson A., Atar D., Casadei B., Castella M.,Diener H.C., Heidbuchel H., Hendriks J., Hindricks G., Manolis A.S., Oldgren J.,Popescu B.A., Schotten U., Van Putte B., Vardas P. et al. 2016 ESC Guidelines forthe management of atrial fibrillation developed in collaboration with EACTS: TheTask Force for the management of atrial fibrillation of the European Society ofCardiology (ESC) Developed with the special contribution of the European HeartRhythm Association (EHRA) of the ESCEndorsed by the European StrokeOrganisation (ESO). // Eur Heart J 2016; doi: 10.1093/eurheartj/ehw210.68.Kubitza D., Becka M., Mueck W.
et al. The effect of extreme age, and gender, onthe pharmacology and tolerability of rivaroxaban— an oral direct Factor Xainhibitor. Blood 2006; 108: Abstract 905.69.Lin I. et al. Real-world Bleeding Risk among Non-Valvular Atrial Fibrillation(NVAF) Patients Prescribed Apixaban, Dabigatran, Rivaroxaban and Warfarin:Analysis of Electronic Health Records.
// Eur Heart J. 2015;36:AbstractSupplement 1084.70.Lindhoff-Last E., Samama M.M., Ortel T.L., Weitz J.I., Spiro T.E.. Assays formeasuring rivaroxaban: their suitability and limitations. Ther Drug Monit.2010;32:673–679.71.Lip G. Y., Frison L., Halperin J.
L.,. Lane D. A. Comparative validation of a novelrisk score for predicting bleeding risk in anticoagulated patients with atrialfibrillation: the HAS-BLED (Hypertension, Abnormal Renal / Liver Function,117Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/AlcoholConcomitantly) score // J Am Coll Cardiol — 2011.— Vol. 57.— P. 173–180.72.Lip G.Y.H., Keshishian A., Kamble S., Pan X., Mardekian J., Horblyuk R.,Hamilton M.
Real-world comparison of major bleeding risk among non-valvularatrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, orwarfarin. A propensity score matched analysis. // Thromb Haemost. 2016; 19; 116(5).73.Lippi G., Favaloro E.J. Activated partial thromboplastin time: new tricks for an olddogma.
// Semin Thromb Hemost. 2008; 34:604–611.74. Lu G., DeGuzman F., Karbarz M.J., et al. Reversal of rivaroxaban mediatedanticoagulation in animal models by a recombinant antidote protein (r-antidote,PRT064445) Paris: 2011. Presented at the European Society of Cardiology Congress.75.Masseria C., et al. Clinical and demographic characteristics according to dosageamong nonvalvular atrial fibrillation patients newly initiated on novel oralanticoagulants.
// European Heart Journal. 2015; 36:Abstract Supplement 1079.76.Massimo Zoni-Berisso, Fabrizio Lercani, Tiziana Carazza, Stefano Domenicucci.Epidemiology of atrial fibrillation: European perspective. Clinical epidemiology2014:6 213-220.77.Miyasaka Y., Barnes M.E., Gersh B.J., et al. Secular trends in incidence of atrialfibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on theprojections for future prevalence. // Circulation 2006; 114:119–125.78.Morishima Y., Kamisato C. Laboratory measurements of the oral direct factor xainhibitor edoxaban: comparison of prothrombin time, activated partialthromboplastin time, and thrombin generation assay. // Am J Clin Pathol.2015;143:241–247.79.Mueck W., Becka M., Kubitza D., Voith B., Zuehlsdorf M. Population model ofthe pharmacokinetics and pharmacodynamics of rivaroxaban – an oral, directFactor Xa inhibitor – in healthy subjects.
// Int J Clin Pharmacol Ther. 2007;45:335–344.11880.Mueck W., Becka M., Kubitza D., Voith B., Zuehlsdorf M. Populationpharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban forthe prevention of venous thromboembolism in patients undergoing total hipreplacement. // Thromb Haemost. 2008; 100:453–461.81.Mueck W., Eriksson B.I., Bauer K.A., Borris L., Dahl O.E., Fisher W.D., Gent M.,Haas S., Huisman M.V., Kakkar A.K., Kälebo P., Kwong L.M., Misselwitz F.,Turpie A.G.
Population pharmacokinetics and pharmacodynamics of rivaroxaban– an oral, direct factor Xa inhibitor – in patients undergoing major orthopaedicsurgery. // Clin Pharmacokinet. 2008; 47:203–216.82.Naccarelli G.V., Varker H., Lin J., Schulman K.L. Increasing prevalence of atrialfibrillation and flutter in the United States. Am J Cardiol 2009;104 (11):1534-9.83.Nakagawa K., Hirai T., Takashima S. et al. Chronic kidney disease and CHADS(2) score independently predict cardiovascular events and mortality in patients withnonvalvular atrial fibrillation // Am J Cardiol — 2011.— Vol.
107.— P. 912–916.84.National guidelines forthe diagnosis and treatment of atrialfibrillation. RationalPharmacother Card 2011;4(suppl):1–80. Russian (Национальные рекомендациипо диагностике и лечению фибрилляции предсердий. РФК 2011; 4(приложение): 1–80.85.Nessel C., Mahaffey K., Piccini J., et al. Incidence and Outcomes ofGastrointestinal Hemorrhage in Patients With Atrial Fibrillation Treated WithRivaroxaban or Warfarin: Results From the ROCKET AF Trial Free To View.CHEST. 2012; 142 (meeting abstracts): 84A–84A.86.Olesen J.B., Lip G.Y., Hansen P.R., et al. Bleeding risk in ‘real world’ patientswith atrial fibrillation: comparison of two established bleeding prediction schemesin a nationwide cohort.
// J Thromb Haemost 2011; 9: 1460–1467.87.Patel M. R., Mahaffey K. W., Garg J.et al. Rivaroxaban versus warfarin innonvalvular atrial fibrillation // N. Eng. J. Med.— 2011.— Vol. 365.— P. 883–891.88.Pfizer Inc. Eliquis Product Monograph (Canada). 2014:1–66.11989.Pisters R., Lane D., Neiwlaat R. et al A novel user-friendly score (HAS-BLED) toassess 1-year risk of major bleeding in patients with atrial fibrillation: the EuroHeart Survey. // Chest, 2010, 138 (5), 1093-1100.90.Pollack C.V.
et al. Idarucizumab for Reversal of the Anticoagulant Effects ofDabigatran in Patients in an Emergency Setting of Major Bleeding, UrgentSurgery, or Interventions. 1130M-05. Presented on 2 April 2016 at the AmericanCollege of Cardiology 65th Annual Scientific Session and Expo, Chicago.91.Rafiq S., Johansson P.I., Kofoed K.F., Olsen P.S. & Steinbrüchel DA (2016)Preoperative hemostatic testing and the risk of postoperative bleeding in coronaryartery bypass surgery patients. // J Card Surg 31(9): 565-571.92.Rohde G. Determination of rivaroxaban – a novel, oral, direct Factor Xa inhibitor– in human plasma by high-performance liquid chromatography – tandem massspectrometry.
// J Chromatogr B Analyt Technol Biomed Life Sci. 2008;872:43–50.93.Roldán V., Marín F., Fernández H., et al. Predictive value of the HAS-BLED andATRIA bleeding scores for the risk of serious bleeding in a 'real world'anticoagulated atrial fibrillation population. // Chest 2012. [Epub ahead of print]DOI 10.1378/chest.12-0608 PubMed PMID: 22722228.94.Russmann S., Gohlke-Barwolf C., Jahnchen E. et al. Age-dependent differences inthe anticoagulant effect of phenprocoumon in patients after heartvalve surgery. //Eur J Clin Pharmacol 1997;52:31-35.95.Sam Mirzaee et al.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
